These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29973293)

  • 1. Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review.
    Zheng G; Cao L; Che Z; Mao E; Chen E; He J
    BMC Pharmacol Toxicol; 2018 Jul; 19(1):41. PubMed ID: 29973293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyxin B-induced skin hyperpigmentation.
    Li YM; Milikowski C; Selvaggi G; Abbo LM; Skiada D; Galimberti F
    Transpl Infect Dis; 2020 Oct; 22(5):e13312. PubMed ID: 32386075
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process.
    Mattos KPH; Cintra ML; Gouvêa IR; Ferreira LÁ; Velho PENF; Moriel P
    J Clin Pharm Ther; 2017 Oct; 42(5):573-578. PubMed ID: 28497462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of polymyxin B resistance in a polymyxin B-susceptible KPC-producing Klebsiella pneumoniae causing bloodstream infection in a neutropenic patient during polymyxin B therapy.
    Zavascki AP; Girardello R; Magagnin CM; Antochevis LC; Maciel RA; Palmeiro JK; Gales AC
    Diagn Microbiol Infect Dis; 2018 Feb; 90(2):134-138. PubMed ID: 29150371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective observational study of the treatment with polymyxin B for liver transplantation recipients infected by multidrug-resistant gram-negative bacteria.
    Yu LL; Shi XP; Huang JF; Gong Y; Cui CX; Wang T
    J Clin Pharm Ther; 2022 Oct; 47(10):1563-1569. PubMed ID: 35670240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nephrotoxicity Associated with Intravenous Polymyxin B Once- versus Twice-Daily Dosing Regimen.
    Okoduwa A; Ahmed N; Guo Y; Scipione MR; Papadopoulos J; Eiras DP; Dubrovskaya Y
    Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29844039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxin B infusion leading to cardiac arrest: a case report and literature review.
    Berie MB; King MS; Thomsen IP
    Infection; 2015 Feb; 43(1):121-4. PubMed ID: 25398485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Temporal evolution of polymyxin B-resistant Klebsiella pneumoniae clones recovered from blood cultures in a teaching hospital during a 7-year period.
    Braun G; Cayô R; Matos AP; de Mello Fonseca J; Gales AC
    Int J Antimicrob Agents; 2018 Mar; 51(3):522-527. PubMed ID: 28887199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare occurrence of polymyxin B-induced hyperpigmentation in a child with ventriculitis.
    Fitzrol DN; Ang SY; Suhaimi A; Yeap TB
    BMJ Case Rep; 2023 Apr; 16(4):. PubMed ID: 37041040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation.
    Zavascki AP; Schuster LF; Duquia RP
    Int J Antimicrob Agents; 2016 Nov; 48(5):579-580. PubMed ID: 27720305
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study.
    Zhang X; Qi S; Duan X; Han B; Zhang S; Liu S; Wang H; Zhang H; Sun T
    J Transl Med; 2021 Oct; 19(1):431. PubMed ID: 34656132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy.
    Zavascki AP; Manfro RC; Maciel RA; Falci DR
    Ann Pharmacother; 2015 Oct; 49(10):1171-2. PubMed ID: 26187742
    [No Abstract]   [Full Text] [Related]  

  • 14. Polymyxin B clinical outcomes: A prospective study of patients undergoing intravenous treatment.
    Mattos KPH; Gouvêa IR; Quintanilha JCF; Cursino MA; Vasconcelos PENS; Moriel P
    J Clin Pharm Ther; 2019 Jun; 44(3):415-419. PubMed ID: 30666679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymyxin B in combination with meropenem against carbapenemase-producing Klebsiella pneumoniae: pharmacodynamics and morphological changes.
    Sharma R; Patel S; Abboud C; Diep J; Ly NS; Pogue JM; Kaye KS; Li J; Rao GG
    Int J Antimicrob Agents; 2017 Feb; 49(2):224-232. PubMed ID: 28040408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mgrB Mutations Mediating Polymyxin B Resistance in Klebsiella pneumoniae Isolates from Rectal Surveillance Swabs in Brazil.
    Aires CA; Pereira PS; Asensi MD; Carvalho-Assef AP
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6969-6972. PubMed ID: 27620478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of ceftazidime-resistant Klebsiella pneumoniae ventriculitis with intravenous meropenem and intraventricular polymyxin B: case report and review.
    Segal-Maurer S; Mariano N; Qavi A; Urban C; Rahal JJ
    Clin Infect Dis; 1999 May; 28(5):1134-8. PubMed ID: 10452648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B.
    Zhou Y; Li Y; Xie X; Song L; Lan G; Sun B; Tang T; Yan H; Zhang B; Xu P
    Br J Clin Pharmacol; 2022 Nov; 88(11):4742-4750. PubMed ID: 35508710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.
    John JF; Falci DR; Rigatto MH; Oliveira RD; Kremer TG; Zavascki AP
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotoxicity in patients treated with intravenous polymyxin B: Two case reports.
    Weinstein L; Doan TL; Smith MA
    Am J Health Syst Pharm; 2009 Feb; 66(4):345-7. PubMed ID: 19202043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.